ACAT1 and adrenal cortex carcinoma: A selective inhibitor of ACAT1 (ATR-101-001) is currently undergoing investigation in a phase I study recruiting patients with advanced ACC (NCT01898715).[84, 85] Based on the premise that many ACCs require substantial intracellular cholesterol as a substrate for steroidogenesis, drugs capable of disrupting cholesterol uptake have therapeutic potential in ACC.